HK1213288A1 - 使用 膜純化細胞結合劑細胞毒性劑綴合物 - Google Patents
使用 膜純化細胞結合劑細胞毒性劑綴合物Info
- Publication number
- HK1213288A1 HK1213288A1 HK16101357.7A HK16101357A HK1213288A1 HK 1213288 A1 HK1213288 A1 HK 1213288A1 HK 16101357 A HK16101357 A HK 16101357A HK 1213288 A1 HK1213288 A1 HK 1213288A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pvdf
- binding agent
- purify cell
- conjugates
- cytotoxic agent
- Prior art date
Links
- 229920002981 polyvinylidene fluoride Polymers 0.000 title 2
- 239000011230 binding agent Substances 0.000 title 1
- 229940127089 cytotoxic agent Drugs 0.000 title 1
- 239000002254 cytotoxic agent Substances 0.000 title 1
- 231100000599 cytotoxic agent Toxicity 0.000 title 1
- 239000012528 membrane Substances 0.000 title 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/265—Adsorption chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/32—Bonded phase chromatography
- B01D15/325—Reversed phase
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/32—Bonded phase chromatography
- B01D15/325—Reversed phase
- B01D15/327—Reversed phase with hydrophobic interaction
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/30—Polyalkenyl halides
- B01D71/32—Polyalkenyl halides containing fluorine atoms
- B01D71/34—Polyvinylidene fluoride
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261709891P | 2012-10-04 | 2012-10-04 | |
PCT/US2013/063480 WO2014055877A1 (en) | 2012-10-04 | 2013-10-04 | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1213288A1 true HK1213288A1 (zh) | 2016-06-30 |
Family
ID=50435472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16101357.7A HK1213288A1 (zh) | 2012-10-04 | 2016-02-04 | 使用 膜純化細胞結合劑細胞毒性劑綴合物 |
Country Status (15)
Country | Link |
---|---|
US (2) | US10035817B2 (zh) |
EP (1) | EP2904089A4 (zh) |
JP (3) | JP6345181B2 (zh) |
CN (2) | CN105209592A (zh) |
AU (2) | AU2013326881B2 (zh) |
CA (1) | CA2886993A1 (zh) |
HK (1) | HK1213288A1 (zh) |
IL (2) | IL238110B (zh) |
IN (1) | IN2015DN03202A (zh) |
MX (1) | MX359599B (zh) |
NZ (1) | NZ707091A (zh) |
RU (2) | RU2661083C2 (zh) |
SG (2) | SG10201702737TA (zh) |
WO (1) | WO2014055877A1 (zh) |
ZA (1) | ZA201502992B (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL282138B2 (en) | 2005-08-24 | 2024-01-01 | Immunogen Inc | A process for preparing purified drug compounds |
BRPI1010620B8 (pt) | 2009-06-03 | 2021-05-25 | Immunogen Inc | métodos de conjugação |
MX369659B (es) | 2011-03-29 | 2019-11-15 | Immunogen Inc | Preparacion de conjugados de maitansinoides y anticuerpos mediante un proceso de una etapa. |
NZ707091A (en) | 2012-10-04 | 2018-12-21 | Immunogen Inc | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
KR102511249B1 (ko) * | 2014-04-29 | 2023-03-20 | 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. | 신규한 안정한 항체-약물 복합체, 이의 제조방법 및 이의 용도 |
WO2016036861A1 (en) | 2014-09-02 | 2016-03-10 | Immunogen, Inc. | Methods for formulating antibody drug conjugate compositions |
CN105797603A (zh) * | 2016-04-13 | 2016-07-27 | 伊美特(上海)环保科技有限公司 | 一种亲水性中空纤维超滤膜及其制备工艺 |
CN106995639A (zh) * | 2017-04-18 | 2017-08-01 | 安徽省康宇水电机械成套设备有限公司 | 一种低成本水下防腐材料 |
CN108549763B (zh) * | 2018-04-09 | 2021-06-01 | 电子科技大学 | 一种用于离子推进器数值模拟的电荷交换碰撞mcc方法 |
CN112830937A (zh) * | 2019-11-22 | 2021-05-25 | 上海医药集团股份有限公司 | 一种美登素dm1聚合物的制备方法 |
CN117042806A (zh) | 2021-03-08 | 2023-11-10 | 启德医药科技(苏州)有限公司 | 抗体-免疫激动剂缀合物及其应用 |
CN117177775A (zh) | 2021-04-14 | 2023-12-05 | 启德医药科技(苏州)有限公司 | 连接子、缀合物及其应用 |
WO2024193570A1 (en) * | 2023-03-21 | 2024-09-26 | Genequantum Healthcare (Suzhou) Co., Ltd. | Combination of antibody-drug conjugate and cancer therapy, and use thereof |
Family Cites Families (166)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE430062B (sv) | 1977-03-04 | 1983-10-17 | Pharmacia Fine Chemicals Ab | Kopplings- eller tioleringsreagens |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
US4563304A (en) | 1981-02-27 | 1986-01-07 | Pharmacia Fine Chemicals Ab | Pyridine compounds modifying proteins, polypeptides or polysaccharides |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4664911A (en) | 1983-06-21 | 1987-05-12 | Board Of Regents, University Of Texas System | Immunotoxin conjugates employing toxin B chain moieties |
EP0397292B1 (fr) | 1985-01-22 | 1993-04-21 | Saint-Gobain Vitrage International | Procédé pour la formation d'une couche mince d'oxydes métalliques sur un substrat, notamment en verre, et son utilisation comme vitrage |
GB8600582D0 (en) | 1986-01-10 | 1986-02-19 | Ca Minister Nat Defence | Purifying biological materials |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4859449A (en) | 1987-09-14 | 1989-08-22 | Center For Molecular Medicine And Immunology | Modified antibodies for enhanced hepatocyte clearance |
US5241078A (en) | 1988-06-14 | 1993-08-31 | Cetus Oncology | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
US5024834A (en) | 1988-07-12 | 1991-06-18 | Cetus Corporation | Thioether linked immunotoxin conjugates |
CA2006408A1 (en) | 1988-12-27 | 1990-06-27 | Susumu Iwasa | Bispecific monoclonal antibody, its production and use |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5714149A (en) | 1989-02-10 | 1998-02-03 | Celltech Therapeutics Limited | Crosslinked antibodies and processes for their preparation |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US6316003B1 (en) | 1989-12-21 | 2001-11-13 | Whitehead Institute For Biomedical Research | Tat-derived transport polypeptides |
US5137877B1 (en) | 1990-05-14 | 1996-01-30 | Bristol Myers Squibb Co | Bifunctional linking compounds conjugates and methods for their production |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
CA2048078A1 (en) | 1990-11-15 | 1992-05-16 | Wolfgang A. Wrasidlo | Chemical modification of antibodies for creation of immunoconjugates |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
SE9102074D0 (sv) | 1991-07-03 | 1991-07-03 | Kabi Pharmacia Ab | Tomour antigen specific antibody |
SE470006B (sv) | 1991-09-26 | 1993-10-25 | Corline Systems Ab | Nytt konjugat, dess framställning och användning samt substrat preparerat med konjugatet |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5556623A (en) | 1993-03-30 | 1996-09-17 | Eli Lilly And Company | Antibody-drug conjugates |
IL111748A0 (en) | 1993-12-03 | 1995-01-24 | Zeneca Ltd | Proteins |
US5747446A (en) | 1994-03-22 | 1998-05-05 | Beth Israel Deaconess Medical Center | Modified polypeptides with increased biological activity |
US5919758A (en) | 1994-03-22 | 1999-07-06 | Beth Israel Deaconess Medical Center | Modified polypeptides with altered biological activity |
US5580853A (en) | 1994-03-22 | 1996-12-03 | New England Deaconess Hospital | Modified polypeptides with increased biological activity |
US5612474A (en) | 1994-06-30 | 1997-03-18 | Eli Lilly And Company | Acid labile immunoconjugate intermediates |
AU5908296A (en) | 1995-05-31 | 1996-12-24 | Fred Hutchinson Cancer Research Center | Compositions and methods for targeted delivery of effector m olecules |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5958872A (en) | 1996-04-01 | 1999-09-28 | Apoptosis Technology, Inc. | Active survival domains of IGF-IR and methods of use |
US6340461B1 (en) | 1996-12-17 | 2002-01-22 | David Stephen Terman | Superantigen based methods and compositions for treatment of diseases |
US6462070B1 (en) | 1997-03-06 | 2002-10-08 | The General Hospital Corporation | Photosensitizer conjugates for pathogen targeting |
US6371975B2 (en) | 1998-11-06 | 2002-04-16 | Neomend, Inc. | Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers |
WO1998056906A1 (en) | 1997-06-11 | 1998-12-17 | Thoegersen Hans Christian | Trimerising module |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US5958677A (en) * | 1997-07-28 | 1999-09-28 | The New York Blood Center, Inc. | Method for purifying viral nucleic acids |
EP1005569A2 (en) | 1997-08-01 | 2000-06-07 | MorphoSys AG | Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex |
US5965714A (en) | 1997-10-02 | 1999-10-12 | Connaught Laboratories, Inc. | Method for the covalent attachment of polysaccharides to protein molecules |
EP1027061B1 (en) | 1997-10-03 | 2005-05-25 | Galenica Pharmaceuticals, Inc. | Imine-forming polysaccharides, preparation thereof and the use thereof as adjuvants and immunostimulants |
US6121236A (en) | 1998-03-24 | 2000-09-19 | The Children's Medical Center Corporation | Multivalent ligands which modulate angiogenesis |
WO1999055715A2 (en) | 1998-04-28 | 1999-11-04 | Galenica Pharmaceuticals, Inc. | Polysaccharide-antigen conjugates |
US5981564A (en) | 1998-07-01 | 1999-11-09 | Universite Laval | Water-soluble derivatives of paclitaxel, method for producing same and uses thereof |
US7067109B1 (en) | 1998-07-13 | 2006-06-27 | Board Of Regents, The University Of Texas System | Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids |
US6780327B1 (en) | 1999-02-25 | 2004-08-24 | Pall Corporation | Positively charged membrane |
TW593241B (en) | 1999-04-20 | 2004-06-21 | Hoffmann La Roche | Carbamic acid derivatives |
AUPQ014799A0 (en) | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using polymers |
CA2385528C (en) | 1999-10-01 | 2013-12-10 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
AU765588C (en) | 1999-11-24 | 2004-12-16 | Immunogen, Inc. | Cytotoxic agents comprising taxanes and their therapeutic use |
NZ518764A (en) | 1999-12-29 | 2004-02-27 | Immunogen Inc | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
EP1257289A1 (en) | 2000-02-08 | 2002-11-20 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
US6596503B1 (en) | 2000-08-18 | 2003-07-22 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
US20060062786A1 (en) | 2000-11-08 | 2006-03-23 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
DZ3494A1 (fr) | 2001-01-05 | 2002-07-11 | Pfizer | Anticorps anti-recepteur du facteur de croissance i analogue a l'insuline |
AU2002240120B2 (en) | 2001-01-29 | 2008-05-08 | Biogen Idec Inc. | Modified antibodies and methods of use |
ATE337011T1 (de) | 2001-02-07 | 2006-09-15 | Beth Israel Hospital | Modifizierte psma-liganden und deren verwendung |
EP1610751A4 (en) | 2001-04-26 | 2006-05-24 | Univ Texas | AGENTE / LIGAND CONJUGATED THERAPEUTIC COMPOSITIONS, METHODS OF SYNTHESIS AND USE THEREOF |
AU2002308637B2 (en) | 2001-05-11 | 2007-05-17 | Board Of Regents, The University Of Texas System | Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26 |
EP1258255A1 (en) | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
WO2002098897A2 (en) | 2001-06-01 | 2002-12-12 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
US6576802B2 (en) | 2001-06-04 | 2003-06-10 | Shell Oil Company | One-step production of 1, 3-propanediol from ethylene oxide and syngas with a catalyst with a phospholanoalkane ligand |
JP2005532415A (ja) | 2001-12-11 | 2005-10-27 | メルク エンド カムパニー インコーポレーテッド | スタフィロコッカス・アウレウスエキソポリサッカライド及び方法 |
US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
EP1467758A4 (en) | 2002-01-03 | 2007-11-14 | Smithkline Beecham Corp | PREPARATION OF IMMUNOCONJUGATES |
US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US6534660B1 (en) | 2002-04-05 | 2003-03-18 | Immunogen, Inc. | CC-1065 analog synthesis |
US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
JP4319979B2 (ja) | 2002-04-26 | 2009-08-26 | ジェネンテック・インコーポレーテッド | タンパク質の非アフィニティ精製 |
LT3127553T (lt) | 2002-05-02 | 2022-04-11 | Wyeth Holdings Llc | Kalicheamicino darinio ir nešiklio konjugatai |
US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
US6596757B1 (en) | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
US20060182740A1 (en) | 2002-06-21 | 2006-08-17 | Biogen Idec, Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
US7390898B2 (en) | 2002-08-02 | 2008-06-24 | Immunogen Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
JP2006500364A (ja) | 2002-08-16 | 2006-01-05 | イムノージェン インコーポレーテッド | 高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用 |
ES2314238T3 (es) | 2002-10-08 | 2009-03-16 | Fresenius Kabi Deutschland Gmbh | Conjugados de oligosacaridos farmaceuticamente activos. |
NZ538993A (en) | 2002-10-30 | 2008-04-30 | Nuevolution As | Method for the synthesis of a bifunctional complex |
CN102875680B (zh) | 2002-11-07 | 2015-04-22 | 伊谬诺金公司 | 抗-cd33抗体和使用其治疗急性髓性白血病的方法 |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
CA2525553C (en) | 2003-05-14 | 2011-07-05 | Immunogen, Inc. | Maytansinoid-antibody conjugate compositions |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
DK1651162T3 (en) | 2003-05-20 | 2016-02-01 | Immunogen Inc | IMPROVED CYTOTOXIC AGENTS WITH NEW MAYTANSINOIDS |
MXPA05014152A (es) | 2003-06-27 | 2006-05-25 | Abgenix Inc | Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos. |
WO2005002597A1 (en) | 2003-07-02 | 2005-01-13 | Polycord, Inc. | Method for delivering polymerized therapeutic agent compositions and compositions thereof |
US20050112130A1 (en) | 2003-11-05 | 2005-05-26 | Bhat Neelima M. | Enhanced B cell cytotoxicity of CDIM binding antibody |
US20050175619A1 (en) | 2004-02-05 | 2005-08-11 | Robert Duffy | Methods of producing antibody conjugates |
US20110064754A1 (en) | 2005-03-03 | 2011-03-17 | Center For Molecular Medicine And Immunology | Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines |
WO2005094882A1 (en) | 2004-03-03 | 2005-10-13 | Millennium Pharmaceuticals, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
WO2005115477A2 (en) | 2004-04-13 | 2005-12-08 | Quintessence Biosciences, Inc. | Non-natural ribonuclease conjugates as cytotoxic agents |
US20060073528A1 (en) | 2004-05-14 | 2006-04-06 | Jean-Michel Lecerf | Measurement methods |
US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
MXPA06013413A (es) | 2004-05-19 | 2007-01-23 | Medarex Inc | Enlazadores quimicos y conjugados de los mismos. |
AU2005249490B2 (en) | 2004-06-01 | 2010-07-29 | Genentech, Inc. | Antibody drug conjugates and methods |
US20060045877A1 (en) | 2004-08-30 | 2006-03-02 | Goldmakher Viktor S | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
TW200630106A (en) | 2004-10-08 | 2006-09-01 | Wyeth Corp | Immunotherapy of autoimmune disorders |
JP2008521828A (ja) | 2004-11-29 | 2008-06-26 | シアトル ジェネティックス, インコーポレイテッド | 操作された抗体およびイムノコンジュゲート |
HUE025449T2 (en) | 2004-12-09 | 2016-04-28 | Janssen Biotech Inc | Immunoconjugates against Integrin, a method for their preparation and use |
US7408030B2 (en) | 2005-01-13 | 2008-08-05 | North Carolina State University | Purification of immunoglobulins using affinity chromatography and peptide ligands |
US20110166319A1 (en) | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
ES2503719T3 (es) | 2005-02-11 | 2014-10-07 | Immunogen, Inc. | Procedimiento para preparar conjugados de anticuerpos y de maitansinoides |
US7678371B2 (en) | 2005-03-04 | 2010-03-16 | Biogen Idec Ma Inc. | Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues |
CA2618721A1 (en) | 2005-04-15 | 2006-10-26 | Immunogen, Inc. | Elimination of heterogeneous or mixed cell population in tumors |
GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
ES2744225T3 (es) | 2005-07-15 | 2020-02-24 | Angiochem Inc | Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos |
WO2007019232A2 (en) | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
IL282138B2 (en) | 2005-08-24 | 2024-01-01 | Immunogen Inc | A process for preparing purified drug compounds |
EP1926498A2 (en) | 2005-09-22 | 2008-06-04 | Hadasit Medical Research Services And Development Company Ltd. | Dextran and arabinogalactan conjugates of therapeutically active compounds |
US20080279868A1 (en) | 2005-09-26 | 2008-11-13 | Medarex, Inc. | Antibody-Drug Conjugates and Methods of Use |
EP1959958A4 (en) | 2005-11-14 | 2010-07-14 | Univ Southern California | INTEGRIN-BINDING SMALL MOLECULES |
US7964415B2 (en) | 2006-04-26 | 2011-06-21 | Cardiogenics Inc. | Stable water-soluble polyethylenimine conjugates and methods of use thereof |
EP2446904B1 (en) | 2006-05-30 | 2015-04-29 | Genentech, Inc. | Anti-CD22 antibodies, their immunoconjugates and uses thereof |
JP5622390B2 (ja) * | 2006-07-18 | 2014-11-12 | サノフイ | 癌治療用対epha2アンタゴニスト抗体 |
US20080213349A1 (en) | 2006-09-11 | 2008-09-04 | Deepak Ramesh Thakker | Liposome Complexes Containing Pharmaceutical Agents and Methods |
WO2008057683A2 (en) * | 2006-10-03 | 2008-05-15 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
PT2019104E (pt) * | 2007-07-19 | 2013-12-03 | Sanofi Sa | Agentes citotóxicos compreendendo novos derivados de tomaimicina e sua utilização terapêutica |
MY157165A (en) * | 2008-04-30 | 2016-05-13 | Immunogen Inc | Cross-linkers and their uses |
SG189817A1 (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
GB0811743D0 (en) | 2008-06-26 | 2008-07-30 | Hemosol Biopharma Inc | Composition |
EP2355799A4 (en) | 2008-11-17 | 2012-09-05 | Enzon Pharmaceuticals Inc | CLEANABLE FUSOGENIC LIPIDS FOR NUCLEIC ACID RELIEF SYSTEMS |
CN102365021B (zh) | 2009-02-05 | 2015-07-15 | 伊缪诺金公司 | 新型苯并二氮杂*衍生物 |
AR076284A1 (es) | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
BRPI1010620B8 (pt) | 2009-06-03 | 2021-05-25 | Immunogen Inc | métodos de conjugação |
FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
AR078471A1 (es) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS |
TW201116297A (en) * | 2009-10-02 | 2011-05-16 | Sanofi Aventis | Antibodies that specifically bind to the EphA2 receptor |
MX340437B (es) | 2010-02-24 | 2016-07-08 | Immunogen Inc | Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos. |
MX338932B (es) | 2010-03-12 | 2016-05-06 | Immunogen Inc | Moleculas de union cd37 y sus inmunoconjugados. |
WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
CA2815277A1 (en) | 2010-10-29 | 2012-05-03 | Immunogen, Inc. | Novel egfr-binding molecules and immunoconjugates thereof |
JP5828902B2 (ja) | 2010-10-29 | 2015-12-09 | イミュノジェン, インコーポレイテッド | 非拮抗性egfr結合分子およびその免疫複合体 |
US20120149732A1 (en) | 2010-12-14 | 2012-06-14 | Alexander Chucholowski | Multifunctional linkers and methods for the use thereof |
EP2675479B1 (en) | 2011-02-15 | 2016-01-13 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
MY171008A (en) * | 2011-03-29 | 2019-09-23 | Immunogen Inc | Preparation of maytansinoid antibody conjugates by a one-step process |
AU2012236403B2 (en) | 2011-03-29 | 2016-08-04 | Immunogen, Inc. | Process for manufacturing conjugates of improved homogeneity |
MX369659B (es) | 2011-03-29 | 2019-11-15 | Immunogen Inc | Preparacion de conjugados de maitansinoides y anticuerpos mediante un proceso de una etapa. |
DK2694106T3 (en) | 2011-04-01 | 2018-03-05 | Immunogen Inc | METHODS FOR INCREASING EFFECT OF FOLR1 CANCER THERAPY |
US20130071482A1 (en) | 2011-09-20 | 2013-03-21 | The University Of Kentucky Research Foundation | Block copolymer cross-linked nanoassemblies as modular delivery vehicles |
US20140350228A1 (en) | 2011-12-13 | 2014-11-27 | Immunogen, Inc. | Use of n-hydroxysuccinimide to improve conjugate stability |
US20150306242A1 (en) | 2012-10-04 | 2015-10-29 | Immunogen, Inc. | Process for preparing stable antibody maytansinoid conjugates |
JP2015535215A (ja) | 2012-10-04 | 2015-12-10 | イムノゲン インコーポレーティッド | 細胞結合剤細胞毒性剤コンジュゲートから不純物を除去するためのイオン交換膜の使用 |
NZ707091A (en) | 2012-10-04 | 2018-12-21 | Immunogen Inc | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
ES2722924T3 (es) | 2012-12-05 | 2019-08-20 | Univ Heidelberg Ruprecht Karls | Conjugados de proteínas y péptidos multivalentes de penetración celular y sus usos |
-
2013
- 2013-10-04 NZ NZ707091A patent/NZ707091A/en not_active IP Right Cessation
- 2013-10-04 WO PCT/US2013/063480 patent/WO2014055877A1/en active Application Filing
- 2013-10-04 CN CN201380061552.7A patent/CN105209592A/zh active Pending
- 2013-10-04 RU RU2015116882A patent/RU2661083C2/ru not_active IP Right Cessation
- 2013-10-04 US US14/430,701 patent/US10035817B2/en not_active Expired - Fee Related
- 2013-10-04 IN IN3202DEN2015 patent/IN2015DN03202A/en unknown
- 2013-10-04 SG SG10201702737TA patent/SG10201702737TA/en unknown
- 2013-10-04 SG SG11201502429YA patent/SG11201502429YA/en unknown
- 2013-10-04 JP JP2015535823A patent/JP6345181B2/ja active Active
- 2013-10-04 EP EP13844268.6A patent/EP2904089A4/en not_active Withdrawn
- 2013-10-04 AU AU2013326881A patent/AU2013326881B2/en not_active Ceased
- 2013-10-04 RU RU2018122734A patent/RU2018122734A/ru not_active Application Discontinuation
- 2013-10-04 MX MX2015004257A patent/MX359599B/es active IP Right Grant
- 2013-10-04 CA CA 2886993 patent/CA2886993A1/en not_active Abandoned
- 2013-10-04 CN CN201810870142.1A patent/CN109200290A/zh active Pending
-
2015
- 2015-04-02 IL IL238110A patent/IL238110B/en active IP Right Grant
- 2015-04-30 ZA ZA201502992A patent/ZA201502992B/en unknown
-
2016
- 2016-02-04 HK HK16101357.7A patent/HK1213288A1/zh unknown
-
2018
- 2018-05-22 JP JP2018097686A patent/JP2018158925A/ja active Pending
- 2018-06-29 US US16/023,005 patent/US20190031712A1/en not_active Abandoned
- 2018-10-03 AU AU2018241056A patent/AU2018241056A1/en not_active Abandoned
-
2019
- 2019-07-31 IL IL268378A patent/IL268378A/en unknown
-
2020
- 2020-02-07 JP JP2020019654A patent/JP2020079294A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ZA201502992B (en) | 2019-10-30 |
MX2015004257A (es) | 2016-02-09 |
CA2886993A1 (en) | 2014-04-10 |
SG10201702737TA (en) | 2017-05-30 |
RU2661083C2 (ru) | 2018-07-11 |
AU2018241056A1 (en) | 2018-10-25 |
IN2015DN03202A (zh) | 2015-10-02 |
RU2015116882A (ru) | 2016-11-27 |
SG11201502429YA (en) | 2015-04-29 |
US10035817B2 (en) | 2018-07-31 |
JP2018158925A (ja) | 2018-10-11 |
US20150225446A1 (en) | 2015-08-13 |
EP2904089A4 (en) | 2016-05-25 |
CN105209592A (zh) | 2015-12-30 |
EP2904089A1 (en) | 2015-08-12 |
IL238110A0 (en) | 2015-05-31 |
RU2018122734A (ru) | 2018-07-24 |
JP6345181B2 (ja) | 2018-06-20 |
CN109200290A (zh) | 2019-01-15 |
AU2013326881A1 (en) | 2015-05-07 |
IL238110B (en) | 2019-08-29 |
JP2020079294A (ja) | 2020-05-28 |
AU2013326881B2 (en) | 2018-08-02 |
US20190031712A1 (en) | 2019-01-31 |
IL268378A (en) | 2019-09-26 |
WO2014055877A1 (en) | 2014-04-10 |
JP2016502501A (ja) | 2016-01-28 |
MX359599B (es) | 2018-09-12 |
NZ707091A (en) | 2018-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL268378A (en) | Using a polyvinyl difluoride membrane to purify conjugates of a cytotoxic factor and a cell-binding factor | |
ZA201605918B (en) | Preparation of cell-binding agent cytotoxic agent conjugates | |
HRP20190576T1 (hr) | Postupci pripreme konjugata | |
ZA201500284B (en) | Plants having increased tolerance to herbicides | |
ZA201305262B (en) | Plants having increased tolerance to herbicides | |
ZA201209112B (en) | Plants having increased tolerance to herbicides | |
GB2501687B (en) | Improvements relating to the transmission of energy | |
EP2764325A4 (en) | USE OF A VIDEOGRAMMETRY FOR THE MANUFACTURE OF PARTS | |
GB2492838B (en) | Improvements relating to pipelaying | |
ZA201403939B (en) | Plants having increased tolerance to herbicides | |
ZA201403938B (en) | Plants having increased tolerance to herbicides | |
EP2674265A4 (en) | BODY OF SHAPED PIPE | |
EP2740420A4 (en) | THERAPEUTIC TOOL | |
HK1203053A1 (zh) | 靶向 的免疫偶聯物的用途 | |
IL222228A0 (en) | Hiv vaccine | |
IL238111A0 (en) | Using an Ion Permeable Membrane to Remove Cytotoxic Factor and Cell Binding Factor Adherent Contaminants | |
HK1196060A1 (zh) | 管形繃帶 | |
EP2754451A4 (en) | USE OF ACHE AS NUCLEASE | |
GB201112134D0 (en) | Improvements relating to pipelaying | |
EP2819577A4 (en) | CO2 MONITORING DEVICE FOR EXPIRY TISSUE | |
AU2012900049A0 (en) | Alternative to a mechanical castration of animals | |
GB201109824D0 (en) | Safe&sound | |
GB201115852D0 (en) | Improvements to sandbags | |
GB201211721D0 (en) | Improvements is or relating to urolgical catheters |